Anupam Rasayan India Ltd (ANURAS) Earnings Call Transcripts

Anupam Rasayan India Ltd's Latest Earnings Call - Q4 FY2026

Anupam Rasayan India Ltd reported its Q4 and FY '26 earnings, marking a significant year with the highest ever revenue. The company achieved a 65% YoY increase in revenue to INR 2,384 crores and an EBITDA margin of 23%. The recent acquisition of Jayhawk Fine Chemicals and the definitive agreement to acquire a stake in Bliss GVS Pharma were highlighted as strategic moves to enhance their specialty chemicals and pharmaceutical platforms. Management maintained a positive outlook, expecting synergies from acquisitions to materialize in FY '27.

Reported metrics

Guidance from management

Management maintained a positive outlook, expecting continued growth with a focus on commercializing new molecules and leveraging synergies from recent acquisitions. No major CapEx is planned, and working capital improvements are expected to continue.

What management said

We should be looking at -- Ankur should be looking at about INR 3,500 crores kind of a number from this revenue -- from this block, at least and then we will look at further optimizing the value optimizing those assets.

I would say over INR 50-odd crores of maintenance CapEx, and then there are some operational efficiency program that we do, and that will be in similar ones less number than I -- so I think INR 50 crores to INR 75 crores is what you can look at CapEx, where will be maintenance and then plus a bit of an efficiency program that we continue to do. But that's the kind of number we are looking at here.

What analysts pressed on

Analysts questioned the rationale behind the Bliss GVS Pharma acquisition, the expected synergies, and the impact on debt levels. Concerns were also raised about the integration of new acquisitions and their contribution to earnings.

Main topics on the call

• Revenue Growth — Revenue for FY '26 was INR 2,384 crores, up 65% YoY. Management attributed this to strong execution across business verticals and diversification into high-performance materials and pharmaceuticals.
• Pharma Segment Expansion — Pharma revenue grew tenfold from INR 21 crores in FY '22 to INR 339 crores in FY '26. Management emphasized the strategic acquisition of Bliss GVS Pharma to strengthen their pharmaceutical platform.
• Acquisition Strategy — The acquisition of Jayhawk Fine Chemicals provides a U.S. manufacturing footprint and access to regulated markets. The Bliss GVS Pharma acquisition aims to create an integrated life sciences platform.
• Operating Cash Flow — Operating cash flow improved to INR 334 crores, driven by better working capital management and operational efficiency.

Read the full Anupam Rasayan India Ltd transcript (Q4 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 12 Anupam Rasayan India Ltd earnings call transcripts on record, spanning January 27, 2023 to May 25, 2026. Based on this history, Anupam Rasayan India Ltd reports quarterly. The most recent call on file is dated May 25, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

ANURAS

Exchange

NSEI

Country

IN

Sector

Materials

Industry

Chemicals

Calls on record

12

First call

January 27, 2023

Most recent

May 25, 2026

Reporting cadence

quarterly